Loading
institutionsInstitution
ISPOR (The Professional Society for Health Economics and Outcomes Research)
The society of health economists and outcomes researchers whose methods and good-practice reports underpin how cancer drugs are valued by HTA bodies and payers.
Also called: ISPORInternational Society for Pharmacoeconomics and Outcomes Research
Overview
Founded in 1995, ISPOR has more than 20,000 members in over 100 countries and publishes Value in Health. Its Good Practices Task Force reports set methodological standards for cost-effectiveness modelling, indirect treatment comparisons, real-world evidence, patient-reported outcomes and value frameworks that health technology assessment agencies including NICE, CADTH and IQWiG reference, and its ISPOR and ISPOR Europe conferences are where HTA bodies, industry and academics debate oncology pricing, surrogate endpoints and managed-access schemes. ISPOR also runs the HTA Roundtables, the Value Assessment Frameworks initiative and a large student network, and it partnered with the FDA and payers on the RWE Transparency Initiative.
Location
Lawrenceville, NJ, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#419 · 12 points (0 Newsweek + 0 NCI + 12 from 6 linked objects) · ranking
- Good Practices Task Force reports
- Value in Health
- ISPOR and ISPOR Europe conferences
- HTA Roundtables and RWE Transparency Initiative
Beth Devine
President (2026-2027)
Health economics and outcomes researchComparative effectivenessHealth technology assessment
Pharmacist-health economist serving as 2026-2027 President of ISPOR, the global society for health economics and outcomes research.
Rob Abbott
Chief Executive Officer
Health economics and outcomes researchAssociation managementHealth policy
Chief Executive Officer of ISPOR, the professional society for health economics and outcomes research.
Similar pages
- IdeaCopy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data
Shares Pharmaceutical Benefits Advisory Committee, Gemeinsamer Bundesausschuss / IQWiG, National Institute for Health and Care Excellence, Real-world evidence.
- TermInnovative Medicines Fund (England)
Shares National Institute for Health and Care Excellence, Real-world evidence, Weak real-world evidence and registries, Prices and value.
- IdeaPower trials to detect a benefit patients would value, not the smallest detectable one
Shares Hazard ratio (HR), Progression-free survival (PFS), Overall survival (OS), Prices and value.
- IdeaOpen, benchmarked algorithms for lines of therapy and progression from routine data
Shares Real-world evidence, Weak real-world evidence and registries, Progression-free survival (PFS).
- PersonMichael LeBlanc
Shares Hazard ratio (HR), Progression-free survival (PFS), Overall survival (OS).
- IdeaA pre-registered standard for emulating trials with real-world data
Shares Hazard ratio (HR), Real-world evidence, Weak real-world evidence and registries.
- IdeaA public rulebook for when an external or synthetic control arm is acceptable
Shares Hazard ratio (HR), Real-world evidence, Weak real-world evidence and registries.
- IdeaPayers fund cancer drugs conditionally on a registry with a pre-specified analysis
Shares Real-world evidence, Weak real-world evidence and registries, Prices and value.